ILK and breast carcinoma: After doxorubicin application on substrates of 10, 38, and 57 kPa in MDA-MB-231 breast cancer cells, the viability of cells on stiffer substrates turned out to be much stronger, and the blocking of integrin-linked kinase (ILK) abrogated the impact of matrix stiffness on the pharmaceutical effect, indicating that matrix stiffness impacts the chemotherapy sensitivity mechanism process through ILK in breast cancer cells [175].